PriceTargets.com logo

Indivior - INDV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 2,515
  • Forecasted Upside: 66.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,514 As of 04/24/2024 10:21 PM ET
▼ -6 (-0.39%)

This chart shows the closing price for INDV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indivior Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INDV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INDV

Analyst Price Target is GBX 2,515
▲ +66.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is GBX 2,515, with a high forecast of GBX 2,700 and a low forecast of GBX 2,330. The average price target represents a 66.12% upside from the last price of GBX 1,514.

This chart shows the closing price for INDV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Indivior. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/3/2023Morgan StanleyBoost TargetGBX 2,500 ➝ GBX 2,700
6/5/2023Jefferies Financial GroupReiterated RatingBuyGBX 2,330
2/16/2023Numis SecuritiesReiterated RatingBuyGBX 2,350
3/25/2022Morgan StanleyInitiated CoverageEqual WeightGBX 330
6/30/2021Numis SecuritiesReiterated RatingBuyGBX 320
1/28/2021Jefferies Financial GroupReiterated RatingBuyGBX 205
1/26/2021CitigroupReiterated RatingBuyGBX 185
1/19/2021Jefferies Financial GroupReiterated RatingBuyGBX 180
7/27/2020Jefferies Financial GroupUpgradeBuyGBX 70 ➝ GBX 200
7/22/2020CitigroupBoost TargetNeutralGBX 45 ➝ GBX 85
6/30/2020Jefferies Financial GroupReiterated RatingHold
6/17/2020Jefferies Financial GroupBoost TargetHoldGBX 39 ➝ GBX 70
2/25/2020CitigroupLower TargetNeutralGBX 58 ➝ GBX 45
1/21/2020Jefferies Financial GroupLower TargetHoldGBX 65 ➝ GBX 39
11/15/2019Jefferies Financial GroupReiterated RatingHold
11/7/2019CitigroupReiterated RatingNeutral
5/2/2019CitigroupReiterated RatingNeutralGBX 150
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Indivior logo
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More

Today's Range

Now: GBX 1,514
Low: 1,496
High: 1,540

50 Day Range

MA: GBX 1,618.62
Low: 1,314
High: 1,764

52 Week Range

Now: GBX 1,514
Low: 1,125
High: 1,938

Volume

401,147 shs

Average Volume

378,314 shs

Market Capitalization

£2.06 billion

P/E Ratio

151,400.00

Dividend Yield

4.48%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Indivior?

The following Wall Street research analysts have issued reports on Indivior in the last twelve months: Jefferies Financial Group Inc., and Morgan Stanley.
View the latest analyst ratings for INDV.

What is the current price target for Indivior?

2 Wall Street analysts have set twelve-month price targets for Indivior in the last year. Their average twelve-month price target is GBX 2,515, suggesting a possible upside of 66.1%. Morgan Stanley has the highest price target set, predicting INDV will reach GBX 2,700 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of GBX 2,330 for Indivior in the next year.
View the latest price targets for INDV.

What is the current consensus analyst rating for Indivior?

Indivior currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INDV will outperform the market and that investors should add to their positions of Indivior.
View the latest ratings for INDV.

What other companies compete with Indivior?

Other companies that are similar to Indivior include HUTCHMED, Hikma Pharmaceuticals, UDG Healthcare, Abcam and Clinigen Group. Learn More about companies similar to Indivior.

How do I contact Indivior's investor relations team?

Indivior's physical mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company's listed phone number is +44-1753-217800. The official website for Indivior is indivior.com. Learn More about contacing Indivior investor relations.